Skip to main content

IMARA Inc. (IMRA)

NASDAQ: IMRA · Delayed Price · USD
3.63
+0.03 (0.83%)
After-hours:Oct 21, 2021 5:22 PM EDT
3.60
-0.03 (-0.83%)
At close: Oct 21, 4:00 PM
Market Cap95.28M
Revenue (ttm)n/a
Net Income (ttm)-47.36M
Shares Out17.72M
EPS (ttm)-2.69
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume78,893
Open3.63
Previous Close3.63
Day's Range3.51 - 3.70
52-Week Range3.51 - 29.92
Betan/a
AnalystsStrong Buy
Price Target24.00 (+566.7%)
Est. Earnings DateNov 4, 2021

About IMRA

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

IndustryBiotechnology
IPO DateMar 12, 2020
Employees27
Stock ExchangeNASDAQ
Ticker SymbolIMRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for IMARA Inc. stock is "Strong Buy." The 12-month stock price forecast is 24.00, which is an increase of 566.67% from the latest price.

Price Target
$24.00
(566.67% upside)
Analyst Consensus: Strong Buy

News

Imara to Participate in Upcoming Investor Conferences

SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference

1 month ago - GlobeNewsWire

Imara to Present at Upcoming Investor Conferences

Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global Healthcare Conference Citi 16th Annual BioPharma Virtual Con...

1 month ago - GlobeNewsWire

Imara Reports Second Quarter 2021 Financial Results and Business Highlights

Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021

2 months ago - GlobeNewsWire

Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sick...

Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022 Interim analysis expected in fourth quarter of 2021 and primary endpoint readout no...

2 months ago - GlobeNewsWire

Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights

BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

2 months ago - GlobeNewsWire

Imara Raises $50M In Equity Funding To Support Development Of Sickle Cell Treatment Candidate

Imara Inc (NASDAQ: IMRA) has priced its previously announced underwritten public offering of shares at $6.00 per share for gross proceeds of $50 million. The offering will close by July 16.

3 months ago - Benzinga

Imara Announces Pricing of Public Offering

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat pa...

3 months ago - GlobeNewsWire

Imara Announces Launch of Proposed Public Offering

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat pa...

3 months ago - GlobeNewsWire

Biotech Losers In 2021 That Could Bounce Big In The Second Half

Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as ...

Other symbols:ATHACCXIIMVTSGTX
3 months ago - Benzinga

Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic...

Imara has continued and expanded the program to award 30 grants totaling $150,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Im...

4 months ago - GlobeNewsWire

Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Co...

Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687

4 months ago - GlobeNewsWire

2 Falling Knives to Catch

Unexpectedly, Wall Street recommends acquiring shares of Protara Therapeutics Inc ( TARA , Financial) and IMARA Inc ( IMRA , Financial), despite the fact that these two equities have shown poor performa...

Other symbols:TARA
4 months ago - GuruFocus

Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual ...

Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial

4 months ago - GlobeNewsWire

Imara Reports First Quarter 2021 Financial Results and Business Highlights

On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021

5 months ago - GlobeNewsWire

Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering ...

5 months ago - GlobeNewsWire

Imara Opens Applications for the Second-Annual ‘Real Impact' Community Support Program to Address Unmet Needs Affecti...

Company will award grants totaling up to $150,000 to nonprofit community-based organizations that support sickle cell disease and beta-thalassemia patients and families Company will award grants totalin...

6 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Investigation of IMARA Inc. Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - March 22, 2021) - Holzer & Holzer, LLC is investigating whether IMARA Inc. ("IMARA" or the "Company") (NASDAQ: IMRA) complied with federal securities laws. On March 5...

6 months ago - Newsfile Corp

Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and...

Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower doses

7 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised ...

7 months ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA).   Such investors are advised to contact R...

7 months ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA

NEW YORK, March 10, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA).  Such investors are advised to contact Rob...

7 months ago - PRNewsWire

Imara Reports Full Year 2020 Financial Results and Business Highlights

Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia

7 months ago - GlobeNewsWire

Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights

BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

7 months ago - GlobeNewsWire

Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering...

8 months ago - GlobeNewsWire

Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biopharmaceutical...

9 months ago - GlobeNewsWire